Chemerin Inhibits Vascular Calcification Through ChemR23 and is Associated with Lower Coronary Calcium in Chronic Kidney Disease

Overview

Journal J Intern Med

Specialty General Medicine

Date 2019 Jun 15

PMID 31197872

Citations 21

Authors

M Carracedo

A Witasp

A R Qureshi

A Laguna-Fernandez

T Brismar

P Stenvinkel

M Back

Affiliations

Soon will be listed here.

Abstract

Background: Chemerin is an adipokine that signals through the G protein-coupled receptor ChemR23 and is associated with inflammation, glucose homeostasis, lipid metabolism and renal function, all of which strongly influence cardiovascular risk. However, elevated chemerin provides a survival advantage in patients with chronic kidney disease (CKD), but how this relates to the cardiovascular phenotype is unknown.

Objectives: The aim of the present study was to establish the association of chemerin with coronary calcification and to determine the effects of chemerin signalling, through ChemR23, in vascular smooth muscle cell (VSMC) calcification.

Methods: Plasma chemerin was measured in 113 patients with CKD and 50 healthy controls. All patients underwent computed tomography to determine coronary artery calcium (CAC) score. VSMCs were isolated from wild-type and ChemR23 knock-out mice and treated with chemerin.

Results: Multivariate analyses established creatinine, cholesterol, body mass index and tumour necrosis factor as significant confounders for circulating chemerin levels. Despite these positive associations with renal function, cardiometabolic risk factors and inflammation, chemerin was inversely associated with CAC both in an age- and sex-adjusted analysis and in a multivariate analysis adjusting for the aforementioned confounders. In addition, circulating chemerin levels were associated with the calcification inhibitors matrix gla protein (MGP) and fetuin-A. Finally, chemerin significantly reduced phosphate-induced calcification and increased MGP expression in VSMCs, whereas chemerin was devoid of these effects in VSMCs lacking ChemR23.

Conclusion: In conclusion, these results suggest that chemerin signalling through ChemR23 in VSMCs protects against vascular calcification in CKD.

Citing Articles

Mineral Stress Drives Loss of Heterochromatin: An Early Harbinger of Vascular Inflammaging and Calcification.

Ho C, Wu M, Thammaphet J, Ahmad S, Ho C S J, Draganova L Circ Res. 2025; 136(4):379-399.

PMID: 39840455 PMC: 11825498. DOI: 10.1161/CIRCRESAHA.124.325374.

Chemerin attenuates acute kidney injury by inhibiting ferroptosis via the AMPK/NRF2/SLC7A11 axis.

Ma Y, Fei S, Chen X, Gui Y, Zhou B, Xiang T Commun Biol. 2024; 7(1):1679.

PMID: 39702678 PMC: 11659585. DOI: 10.1038/s42003-024-07377-x.

Chemerin in the Spotlight: Revealing Its Multifaceted Role in Acute Myocardial Infarction.

Mitsis A, Khattab E, Myrianthefs M, Tzikas S, Kadoglou N, Fragakis N Biomedicines. 2024; 12(9).

PMID: 39335646 PMC: 11428948. DOI: 10.3390/biomedicines12092133.

Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.

Ghanem L, Essayli D, Kotaich J, Al Zein M, Sahebkar A, Eid A J Cell Physiol. 2024; 239(12):e31424.

PMID: 39188012 PMC: 11649971. DOI: 10.1002/jcp.31424.

Causal Association of Arterial Stiffness With the Risk of Chronic Kidney Disease.

Tian X, Chen S, Xia X, Xu Q, Zhang Y, Zhang X JACC Asia. 2024; 4(6):444-453.

PMID: 39100705 PMC: 11291385. DOI: 10.1016/j.jacasi.2023.10.010.

References

Gu P, Cheng M, Hui X, Lu B, Jiang W, Shi Z . Elevating circulation chemerin level is associated with endothelial dysfunction and early atherosclerotic changes in essential hypertensive patients. J Hypertens. 2015; 33(8):1624-32. DOI: 10.1097/HJH.0000000000000588. View

Yoo H, Choi H, Yang S, Kim H, Seo J, Kim S . Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb. 2011; 19(1):59-66. DOI: 10.5551/jat.9647. View

Yamamoto T, Qureshi A, Anderstam B, Heimburger O, Barany P, Lindholm B . Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant. 2010; 25(12):4017-23. DOI: 10.1093/ndt/gfq329. View

Lehrke M, Becker A, Greif M, Stark R, Laubender R, von Ziegler F . Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009; 161(2):339-44. DOI: 10.1530/EJE-09-0380. View

Lopez-Vicario C, Rius B, Alcaraz-Quiles J, Gonzalez-Periz A, Martinez-Puchol A, Casulleras M . Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. Sci Rep. 2017; 7(1):15724. PMC: 5691181. DOI: 10.1038/s41598-017-15951-z. View

Herenius M, Oliveira A, Wijbrandts C, Gerlag D, Tak P, Lebre M . Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation. PLoS One. 2013; 8(2):e57802. PMC: 3584053. DOI: 10.1371/journal.pone.0057802. View

Carracedo M, Artiach G, Witasp A, Claria J, Carlstrom M, Laguna-Fernandez A . The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. Cardiovasc Res. 2019; 115(10):1557-1566. DOI: 10.1093/cvr/cvy316. View

Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M . Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care. 2009; 33(1):171-3. PMC: 2797967. DOI: 10.2337/dc09-1351. View

Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G . Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148(10):4687-94. DOI: 10.1210/en.2007-0175. View

10.

Sell H, Divoux A, Poitou C, Basdevant A, Bouillot J, Bedossa P . Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010; 95(6):2892-6. DOI: 10.1210/jc.2009-2374. View

11.

Gregory C, Gunn W, Peister A, Prockop D . An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem. 2004; 329(1):77-84. DOI: 10.1016/j.ab.2004.02.002. View

12.

Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R . Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens. 2002; 15(12):1101-8. DOI: 10.1016/s0895-7061(02)03029-7. View

13.

Wilkinson I, MacCallum H, Flint L, Cockcroft J, Newby D, Webb D . The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000; 525 Pt 1:263-70. PMC: 2269933. DOI: 10.1111/j.1469-7793.2000.t01-1-00263.x. View

14.

Back M, Powell W, Dahlen S, Drazen J, Evans J, Serhan C . Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014; 171(15):3551-74. PMC: 4128057. DOI: 10.1111/bph.12665. View

15.

Dong B, Ji W, Zhang Y . Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med. 2011; 50(10):1093-7. DOI: 10.2169/internalmedicine.50.5025. View

16.

Rutkowski P, Sledzinski T, Zielinska H, Lizakowski S, Goyke E, Szrok-Wojtkiewicz S . Decrease of serum chemerin concentration in patients with end stage renal disease after successful kidney transplantation. Regul Pept. 2011; 173(1-3):55-9. DOI: 10.1016/j.regpep.2011.09.005. View

17.

Hu W, Feng P . Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract. 2010; 91(2):159-63. DOI: 10.1016/j.diabres.2010.11.016. View

18.

Carracedo M, Back M . Fetuin A in aortic stenosis and valve calcification: Not crystal clear. Int J Cardiol. 2018; 265:77-78. DOI: 10.1016/j.ijcard.2018.04.115. View

19.

Leiherer A, Muendlein A, Kinz E, Vonbank A, Rein P, Fraunberger P . High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events - Insights from phenotype and genotype characterization. Vascul Pharmacol. 2015; 77:60-8. DOI: 10.1016/j.vph.2015.08.010. View

20.

Ferland D, Watts S . Chemerin: A comprehensive review elucidating the need for cardiovascular research. Pharmacol Res. 2015; 99:351-61. PMC: 4859430. DOI: 10.1016/j.phrs.2015.07.018. View